glofitamab
An investigational T-cell–engaging bispecific antibody being developed for aggressive lymphomas
Glofitamab is a T-cell–engaging bispecific antibody that is designed to bind bivalently to CD20 on B cells and monovalently to CD3 on T cells through its distinctive 2:1 structure that may enable high-avidity binding to CD20 on B cells1
CD=cluster of differentiation.